The Cardiovascular Research Foundation^® (CRF^®) proudly announces the appointment of Dr. Jeffrey Popma as Chief Scientific and Strategic Officer. A world-renowned leader in cardiovascular research, Dr. Popma will drive forward pivotal programs and initiatives that will shape CRF’s future and fuel innovation at the CRF^® Clinical Trials Center (CTC). His leadership will be instrumental in the development of the recently launched Real-World Data and Outcomes Center, advancing CRF’s commitment to impactful research. Additionally, as Program Director for New York Valves and TCT^® (Transcatheter Cardiovascular Therapeutics^®), CRF’s flagship scientific meeting, Dr. Popma will play a key role in guiding the organization’s transformative contributions to the field of cardiovascular medicine.

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically causes mild, cold-like symptoms in most adults but can be deadly for infants—during weeks 32–36 of pregnancy. New research led by investigators at Mass General Brigham suggests that vaccination earlier in that timeframe, closer to 32 weeks, could provide the best protection for newborns against RSV. The findings are published in the American Journal of Obstetrics & Gynecology.